# Ichnos Glenmark files US FDA application for solid tumour drug

2026-11-17T17:48:09+00:00 | Business & Economy | Indian Opinion Desk

Corroboration: 2 independent outlets
Outlets counted: business-standard.com, cnbctv18.com

Ichnos Glenmark Innovation (IGI), the biotechnology joint venture of Glenmark Pharmaceuticals and Ichnos Sciences, has submitted an investigational new drug (IND) application to the US FDA for ISB 2301, a candidate designed to target solid tumours. The company plans to initiate a Phase I clinical trial in 2027, subject to regulatory clearance. ISB 2301 is a pentaspecific molecule designed to target three tumour-associated antigens while activating T cells and natural killer (NK) cells. It was developed using IGI's proprietary BEAT multispecific platform. In preclinical studies, the drug showed favourable pharmacokinetic and tolerability profiles in non-human primates. The company is also developing ISB 2001 for multiple myeloma, which has shown anti-tumour activity in an early-stage trial. Glenmark's shares closed at ₹2,613.80 on 17 November.

## Indian Opinion Analysis

Business Standard leads with the scientific details of ISB 2301's pentaspecific design and Lida Pacaud's statement, framing the IND filing as a milestone for IGI's oncology pipeline. CNBC TV18's version is more market-sensitive, adding Glenmark's share price movement (closing at ₹2,613.80, down 0.6%) and a disclaimer about preclinical results being animal studies only. The two outlets are otherwise uniform, carrying the same corporate announcement from the regulator. Neither adopts a critical or ideological stance. The balanced reading is that IGI has taken a defined regulatory step toward a Phase I trial in 2027, with the drug's actual clinical profile yet to be tested.

## Coverage

Coverage: 2 sources, 2 neutral
- business-standard.com (neutral report) <https://www.business-standard.com/industry/news/ichnos-glenmark-files-us-fda-application-for-solid-tumour-drug-isb-2301-126111701400_1.html>
  Leads with scientific detail and executive quote
- cnbctv18.com (neutral report) <https://www.cnbctv18.com/business/companies/glenmark-pharma-announces-usfda-filing-for-isb-2301-an-immune-cell-activator-targeting-solid-tumours-20036202.htm>
  Adds share price and preclinical disclaimer

This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry.

Tags: Glenmark Pharmaceuticals, Ichnos Glenmark Innovation, ISB 2301, US FDA
Canonical: https://indianopinion.org/ichnos-glenmark-files-us-fda-application-for-solid-tumour-drug/
License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources.
Cite: https://indianopinion.org/ichnos-glenmark-files-us-fda-application-for-solid-tumour-drug/#story-in-brief
Gate decision: pass (pass: linked qualifying outlets 2 of 2, relevance 7)
Freshness: pass (fresh: newest qualifying source 2026-11-17 17:10Z (feed), 0.6 h old)
Image: photograph. Source: https://bsmedia.business-standard.com/_media/bs/img/article/2020-02/14/thumb/fitandfill/1200X628/1581692409-1726.png.

How this brief was made: an AI model read the reports linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. Stance labels are editorial classifications of how each outlet framed this story, assigned by the same model, not ratings of the outlets. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/
